Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Robinan Gentry

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Critical Reviews in Toxicology|May 29, 2024
A framework for integrating evidence to assess hazards and riskSandra I Sulsky, Tracy Greene, P Robinan Gentry
Regulatory Toxicology and Pharmacology : RTP|July 25, 2003
Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactationP Robinan Gentry, Tammie R Covington, Harvey J Clewell
Regulatory Toxicology and Pharmacology : RTP|April 4, 2018
Quantitative risk assessment of tobacco products: A potentially useful component of substantial equivalence evaluationsKristin M Marano, Charlene Liu, William Fuller, et al.
Journal of Toxicology and Environmental Health. Part A|September 20, 2018
Application of the adverse outcome pathway (AOP) approach to inform mode of action (MOA): A case study with inorganic arsenicHarvey J Clewell, Janice W Yager, Tracy B Greene, et al.
Critical Reviews in Toxicology|August 16, 2005
Evaluation of physiologically based pharmacokinetic models in risk assessment: an example with perchloroethyleneHarvey J Clewell, P Robinan Gentry, Janet E Kester, et al.
International Archives of Occupational and Environmental Health|September 4, 2013
Potential occupational risk of amines in carbon capture for power generationP Robinan Gentry, Tamara House-Knight, Angela Harris, et al.
Journal of Toxicology and Environmental Health. Part A|November 13, 2003
Application of a physiologically based pharmacokinetic model for reference dose and reference concentration estimation for acetoneP Robinan Gentry, Tammie R Covington, Harvey J Clewell, et al.
Regulatory Toxicology and Pharmacology : RTP|October 30, 2016
The need for transparency and reproducibility in documenting values for regulatory decision making and evaluating causality: The example of formaldehydeCynthia Van Landingham, Kenneth A Mundt, Bruce C Allen, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 22, 2002
An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathionP Robinan Gentry, C Eric Hack, Lynne Haber, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|August 1, 2020
A Kinetic Analysis of DNA-Deoxy Guanine Adducts in the Nasal Epithelium Produced by Inhaled Formaldehyde in Rats-Assessing Contributions to Adduct Production From Both Endogenous and Exogenous Sources of FormaldehydeJerry L Campbell, P Robinan Gentry, Harvey J Clewell Iii, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Critical Reviews in Toxicology|May 29, 2024
A framework for integrating evidence to assess hazards and riskSandra I Sulsky, Tracy Greene, P Robinan Gentry
Regulatory Toxicology and Pharmacology : RTP|July 25, 2003
Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactationP Robinan Gentry, Tammie R Covington, Harvey J Clewell
Regulatory Toxicology and Pharmacology : RTP|April 4, 2018
Quantitative risk assessment of tobacco products: A potentially useful component of substantial equivalence evaluationsKristin M Marano, Charlene Liu, William Fuller, et al.
Journal of Toxicology and Environmental Health. Part A|September 20, 2018
Application of the adverse outcome pathway (AOP) approach to inform mode of action (MOA): A case study with inorganic arsenicHarvey J Clewell, Janice W Yager, Tracy B Greene, et al.
Critical Reviews in Toxicology|August 16, 2005
Evaluation of physiologically based pharmacokinetic models in risk assessment: an example with perchloroethyleneHarvey J Clewell, P Robinan Gentry, Janet E Kester, et al.
International Archives of Occupational and Environmental Health|September 4, 2013
Potential occupational risk of amines in carbon capture for power generationP Robinan Gentry, Tamara House-Knight, Angela Harris, et al.
Journal of Toxicology and Environmental Health. Part A|November 13, 2003
Application of a physiologically based pharmacokinetic model for reference dose and reference concentration estimation for acetoneP Robinan Gentry, Tammie R Covington, Harvey J Clewell, et al.
Regulatory Toxicology and Pharmacology : RTP|October 30, 2016
The need for transparency and reproducibility in documenting values for regulatory decision making and evaluating causality: The example of formaldehydeCynthia Van Landingham, Kenneth A Mundt, Bruce C Allen, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 22, 2002
An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathionP Robinan Gentry, C Eric Hack, Lynne Haber, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|August 1, 2020
A Kinetic Analysis of DNA-Deoxy Guanine Adducts in the Nasal Epithelium Produced by Inhaled Formaldehyde in Rats-Assessing Contributions to Adduct Production From Both Endogenous and Exogenous Sources of FormaldehydeJerry L Campbell, P Robinan Gentry, Harvey J Clewell Iii, et al.
Pageof 5